CRISPR Therapeutics
VerifiedGene-based medicines for patients with serious diseases
Launch date
Employees
Ownership
Market cap
$4.7b
Net debt
$4.9b
Firm valuation
$5.3b (Public information from Jan 2022)
Share price
$60.77 CRSP
Basel Canton of Basel-Stadt (HQ)
RELATED LANDSCAPES AND LISTS
Financials
Edit| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 41m | 3m | 290m | - | 904m | 12m |
| % growth | - | - | (93 %) | 9567 % | - | - | (99 %) |
| EBITDA | - | (61m) | (155m) | 51m | (345m) | 389m | (726m) |
| % EBITDA margin | - | (149 %) | (5167 %) | 18 % | - | 43 % | (6050 %) |
| Profit | - | (68m) | (165m) | 66m | (349m) | 387m | (639m) |
| % profit margin | - | (166 %) | (5500 %) | 23 % | - | 43 % | (5325 %) |
| EV / revenue | - | 23.5x | 330.0x | 9.3x | 13420.0x | 6.3x | 229.0x |
| EV / EBITDA | - | - | -6.6x | 52.0x | -27.9x | - | -4.0x |
| R&D budget | - | - | 107m | 176m | - | - | - |
| R&D % of revenue | - | - | 3557 % | 61 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
| €22.5m | Series A | ||
| $64m | Series B | ||
* | €38m | Series B | |
| N/A | $56m Valuation: $626m | IPO | |
| N/A | N/A | Grant Not yet verified | |
| Total Funding | $131m | ||
Recent News about CRISPR Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.